Key Drivers
- Strong liquidity
- High leverage
- Heavy intangibles
AIAI Summary
Amphastar's pivot to higher‑margin branded injectables creates real upside optionality, but the investment is now execution‑binary—Baqsimi commercialization, Ipratropium HFA launch, and on‑time capacity scale‑up over the next 2–4 quarters must succeed to justify the re‑rating or else impairments, margin erosion and further downside are likely.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •High leverage
- •Heavy intangibles
AMPH combines strong liquidity, margins and free cash flow with material leverage and large intangible assets that increase impairment and long‑term solvency risk.
Price Behavior
Key Price Behavior Insights:
- •Strong downtrend
- •Sharp gap-down
- •Narrow trading band
Over last month AMPH plunged ~32% from $28.53 to $19.50—driven by a sharp late‑Feb gap into the low $20s, it has since stabilized around $19–$19.5 with support near $18.18 and resistance at ~$20.4–$21, leaving the bias bearish until it reclaims ~$21–$22.
Sharp gap from $26.49 to $20.23 around 2026-02-26–02-27 indicating a one-time sell shock
Sentiment & News
Key News Insights:
- •EPS miss
- •Guidance cut
- •FDA win
Amphastar missed Q4 EPS, cut FY26 revenue guidance and warned of margin pressure from declining generics and higher costs despite an FDA approval for Ipratropium Bromide HFA.
Near-term downside risk dominates as cost pressures and legacy-product declines likely weigh on the stock despite potential long-term upside from new branded launches
Similar Companies in Healthcare
Other companies in the same sector with AI ratings